Tissular plasminogen activator as prognostic factor in patients with myocardial infarction;Activador tisular del plasminógeno como factor pronóstico en pacientes con infarto de miocardio

Revista Clinica Espanola

Volumn 199, Issue 4, 1999, Pages 215-217

  Fernandez Abellan P ^a   Marin Ortuno F ^b   Marco Vera, P ^b   Lujan Martinez J ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PROGNOSIS; RISK FACTOR;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN INACTIVATORS; PROGNOSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 0033113001     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of the coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326:310-318.
2. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. Lancet 1996; 348 (suppl 1):7S-10S.
3. Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pecto ris. N Engl J Med 1995; 332:635-641.
4. Juhan-Vague I, Pyke S, Alessi MC, Jespersen J, Haverkate F, Thomp son SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94:2.057-2.063.
5. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997; 337:1.360-1.309.
6. Angles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erytematosus. J Lab Clin Med 1979; 94:313-323.
7. Greaves M, Pickerin C, Knight G, et al. Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endotelial cell damage? Diabetologia 1987; 30:160-165.
8. Killip T, Kimball JL. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457-461.
9. Marín E, Valle V, Abeytua M, et al. Estratificación pronóstica después del infarto de miocardio. Prevención secundaria y rehabilitación. Rev Esp Cardiol 1994; 47 (1):49-61.
10. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller JG. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1.076-1.079.
11. Van de Loo. Circulating factors of the haemostatic systems as indicators of increased or reduced coronary risk. British J Haemat 1995; 91: 777-782.
12. Cooper J, Douglas AS. Fibrinogenen level as a predictors of mortality in survivors of myocardial infarction. Fibrinolysis 1991; 5:105-108.
13. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial and death. Br Heart J 1991; 66:351-355.
14. Ridker P, Vaugman D, Stampfer M, Manson J, Hennekens C. Endogenous tissue-type plasninogen activator and risk or myocardial infarction. Lancet 1993; 341:1.165-1.198.
15. Harnstein A. Hemostatic function and coronary artery disease. N Engl J Med 1995; 332(10):677-678